Triangle gains public company with merger Breakthrough! RTP biotech sees progress in restoring vision to blind Breakthrough!

The therapy, which delivers COL7A1 transgenes by eyedrop, was used previously to treat a patient under a compassionate use protocol.

Topline data were announced from a phase 3 trial evaluating ST-100 ophthalmic solution for the treatment of dry eye disease.

The trial is evaluating KB803 for the treatment and prevention of corneal abrasions in dystrophic epidermolysis bullosa ...